FDA Finalizes Guidance on Developing Drugs to Treat Severe Hematologic Disorders

Drug Industry Daily
A A
The FDA issued final guidance for developers of drugs to treat severely debilitating or life-threatening hematologic disorders (SDLTHDs), such as hemophilia and sickle cell disease.

To View This Article:

Login

Subscribe To Drug Industry Daily